VIVITRA 440 MG is a high-concentration targeted biological therapy containing Trastuzumab, a monoclonal antibody essential for treating specific aggressive cancers. Manufactured by Zydus Lifesciences (Cadila), it is a premium biosimilar to the global brand Herceptin. Vivitra works by specifically binding to the HER2 (Human Epidermal Growth Factor Receptor 2) protein, which is found in high amounts on the surface of certain cancer cells. By blocking this receptor, it halts the growth signals of the tumor and recruits the body’s immune system to destroy the cancer cells. It is a critical treatment for HER2-positive breast cancer and metastatic gastric (stomach) cancer.
United States
United Kingdom
Australia
Canada
CN
Thailand
Singapore
Reviews
There are no reviews yet